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Abstract
An animal model for the early detection of common fatal diseases such as ischemic diseases and cancer is desirable for the
development of new drugs and treatment strategies. Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that
regulates oxygen homeostasis and plays key roles in a number of diseases, including cancer. Here, we established
transgenic (Tg) mice that carry HRE/ODD-luciferase (HOL) gene, which generates bioluminescence in an HIF-1-dependent
manner and was successfully used in this study to monitor HIF-1 activity in ischemic tissues. To monitor carcinogenesis in
vivo, we mated HOL mice with rasH2 Tg mice, which are highly sensitive to carcinogens and are used for short-term
carcinogenicity assessments. After rasH2-HOL Tg mice were treated with N-methyl-N-nitrosourea, bioluminescence was
detected noninvasively as early as 9 weeks in tissues that contained papillomas and malignant lesions. These results suggest
that the Tg mouse lines we established hold significant potential for monitoring the early onset of both ischemia and
carcinogenesis and that these lines will be useful for screening chemicals for carcinogenic potential.
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Introduction
Hypoxia-inducible factors (HIFs) are transcription factors
essential for cellular adaptation to hypoxia. More than 100
putative HIF direct target genes have been identified, and many of
these are involved in adaptive processes to hypoxia [1]. HIF-1, the
most abundant and ubiquitously expressed HIF, is composed of a
hypoxia-inducible a subunit (HIF-1a) and a constitutively
expressed b subunit (HIF-1b) [1]. Under well-oxygenated
conditions, HIF-1a is hydroxylated by members of the prolyl
hydroxylase domain (PHD) family, which target highly conserved
prolyl residues (Pro402 and Pro564) located in the HIF-1a oxygen-
dependent degradation (ODD) domain [1–4]. Trans-4-prolyl-
hydroxylation of HIF-1a enables it to be recognized by the von
Hippel-Lindau tumor suppressor protein (pVHL), a component of
ubiquitin ligase complexes [3,4]. As a result, HIF-1a is
polyubiquitinated and undergoes proteasomal degradation [1–4].
Hypoxia suppresses the rate of HIF-1a hydroxylation, allowing
HIF-1a to accumulate and translocate to the nucleus, where it
heterodimerizes with HIF-1b to form an active transcription factor
[1].
In addition to its oxygen-dependent, post-translational regula-
tion, HIF-1a is regulated at various other levels, including
transcription, translation, and PHD-independent protein degra-
dation. In cancer cells, for example, insulin and certain growth
factors are known to increase HIF-1a protein synthesis in a 59
untranslated region-dependent manner via the activation of the
phosphatidylinositol 3-kinase/Akt pathway and mTOR signaling
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e26640[5,6]. Moreover, HIF-1a protein synthesis has been reported to be
regulated by the RNA-binding proteins HuR and PTB and by the
stress-induced phosphorylation of eIF2a [7–9]. There is also
evidence for pathways that control HIF-1a stability in an oxygen-
independent manner. For instance, Hsp90 inhibitors and the
transcription factor FOXO-4 have been reported to induce the
degradation of HIF-1a in a pVHL-independent manner [10–13].
Furthermore, genetic changes in oncogenes such as raf and p53
have been shown to increase HIF-1a expression [1,14–17].
In cancers, a number of the genes induced by HIF-1 are
critically involved in processes such as immortalization, cellular
differentiation, genetic instability, vascularization, metabolic
reprogramming, autocrine growth factor signaling, invasion/
metastasis, and resistance to treatment [1,2,14]. Therefore, HIF
activity is potentially an excellent candidate for use as a marker of
cancer formation. Recently we constructed an HRE/ODD-luciferase
(HOL) vector [18] consisting of a HIF-1-dependent promoter and
a cDNA encoding firefly luciferase fused to the sequence for the
ODD domain (548–603) of human HIF-1a [19]. As a result of the
PHD regulation of HIF through the ODD domain, the in vivo half-
life of luciferase was shortened from ,5 h to less than 17 min in
the presence of a normal partial pressure of oxygen. This
shortened half-life resulted in the avoidance of the prolonged
accumulation of luciferase protein in cells lacking HIF-1 activity
and thereby allowed a more precise detection of HIF-1 activity.
Whole-body bioluminescent imaging is a highly versatile and
powerful tool for obtaining biological information from small
animals in a noninvasive manner [20]. Bioluminescent imaging
relies on the activity of enzymes that convert unique substrates into
light and have enabled the monitoring of transgene expression in
genetically engineered mice [21]. Bioluminescence at the emission
wavelength of firefly luciferase (560 nm) can be imaged as deep as
several centimeters within the tissue, which allows a resolution to
at least the organ level.
In this study, we have constructed HOL Tg mice, which
generate bioluminescence in a HIF-1-dependent manner. For
monitoring tumor formation in vivo, HOL Tg mice were mated
with rasH2 Tg mice [22], which show a higher sensitivity to
carcinogens than conventional mice [23] and have been used for
short-term carcinogenicity assessments as an alternative to the
traditional 2-year mice bioassays [24]. bioluminescence was
noninvasively detected as early as 9 weeks after treatment with
N-methyl-N-nitrosourea (MNU), and the tissues with the biolumi-
nescence contained papillomas and carcinomas. Overall, the
results demonstrated that the Tg mice we developed can be used
as mouse models for in vivo bioimaging in order to study the onset
and progression of ischemic diseases and cancers.
Results
Development and characterization of Tg mice for
monitoring HIF-1 activity
To noninvasively monitor HIF-1 activity, we generated several
HOL Tg mouse lines (Figure 1A) in the BALB/c and FVB/N
backgrounds (BALB/HOL and FVB/HOL, respectively). The
HOL transgene expresses the ODD-luciferase fusion protein under
the HIF-1-dependent promoter HRE and therefore generates
bioluminescence in HIF-1 active cells. Moreover, the ODD-fusion
protein is degraded quickly in HIF-inactive cells [18,25], allowing
real-time monitoring of HIF-1 activity in mice. Peritoneal
injections with the antioxidant reagent propyl gallate (PG) were
used to select for mouse lines with good induction of the
bioluminescence signal (Figure 1B) since PG inhibits HIF prolyl
hydroxylase and effectively stabilizes HIF-1 [26]. PG treatment
can enable a significant HIF-1-induced bioluminescence signal to
be observed over background bioluminescence (Figure S1).
Among the different lines, line 1 of BALB/HOL Tg mice and
line 3 of FVB/HOL Tg mice showed reliable expression of the
transgene after PG treatment. Both lines were each found to carry
a single copy of the transgene (Figure 1C). FVB/HOL line 3 was
found to carry the transgene in chromosome 19, the smallest of the
chromosomes (Figure S2). Since this line also showed a sharp
turning on/off of HOL gene expression, we primarily used this line
in the subsequent studies.
Luciferase reporter response in cells derived from HOL Tg
mice
In an initial study, we examined the in vitro and ex vivo reporter
response to hypoxia-induced HIF-1 activity by using cells isolated
from FVB/HOL mice. Mouse embryo fibroblast (MEF) cells were
cultured under hypoxic conditions, and their luciferase activity was
measured. Luciferase activity in the MEF cells was expressed at
significantly higher levels relative to that of the control 12 h after
exposure to hypoxia (1% O2) (Figure 2A). RT-PCR was then used
to examine the expression of the transgene in tissues isolated from
FVB/HOL mice 2 h after peritoneal injection of PG. All
examined tissues were found to express the reporter transcript
(Figure 2B). The expression of the luciferase reporter was further
confirmed by using tissues isolated from the FVB/HOL mice 2 h
after the peritoneal injection of PG. Significant bioluminescence
was detected in the tissues from the PG-treated FVB/HOL mice
but not in those from PG-treated non-Tg mice (Figure 2C). These
results demonstrated that the transgene in the HOL Tg mice could
be used to monitor HIF-1 activity in vitro and ex vivo.
Monitoring of HIF-1 activity in vivo
Next, we examined the reporter response to HIF-1 activity in
vivo. Initially, we monitored bioluminescence after birth. The
bioluminescence signal was the highest 1 day after birth and
quickly decreased afterwards during the first week (Figures 3A and
3B), while no bioluminescence was detected in non-Tg mice
(Figure S3). Within the third week after birth, the bioluminescence
signal was at a basal level for the entire body (Figures 3A and 3B)
and was at the same background level as that of non-Tg mice
(Figure S1). Subsequently, we monitored bioluminescence after
ischemic treatment of 8-week-old mice. The femoral artery was
ligatured proximally and distally and then cut between the
ligatures without damaging the femoral nerve. A sham operation
was performed on the ipsilateral side. After the operation,
bioluminescence imaging was performed sequentially, starting
from 0 h till the next 12 days (Figure 3C). A significantly high
bioluminescence signal was detected in the ligatured leg 2 h after
the operation and continued until 12 days after the operation. For
confirming the increase of HIF activity in the ligatured leg, the
mRNA of ischemic hind limb tissues was isolated 7 days after the
operation. The level of GLUT1, a HIF-1 target gene, was then
quantified by using semi-quantitative real-time RT-PCR. GLUT1
expression was found to be significantly increased in the ischemic
hind limb compared to that in the sham-operated one (Figure 3D).
These results showed that HIF-1 activation can be monitored with
HOL Tg mice.
Incidence of MNU-induced tumors in Tg F1 mice with H-
ras and HOL transgenes
To investigate HIF-1 activity during tumor development in vivo,
we mated HOL mice with rasH2 mice to generate rasH2-HOL
mice. Because the black coat of rasH2 mice is an obstacle for
Transgenic Mice for Bioimaging of Carcinogenesis
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albino-rasH2 mice; these were established by mating rasH2 mice
to B6-Tyr
c (B6-albino) mice, which carry a tyrosinase gene
mutation that results in a recessive albino phenotype. Before
monitoring HIF activity in rasH2-HOL mice after MNU
treatment, we examined the influence of HOL and Tyr
c transgenes
and the weekly treatment of luciferin on the incidence of MNU-
induced tumors in rasH2 mice. In accordance with an established
6-month protocol for a carcinogenicity assessment of rasH2 mice,
the white-coated B6-albino-rasH2 mice were mated with the
BALB/HOL mice, and the MNU-induced tumor incidence was
examined in the F1 mice, which segregated according to the
expected 4 genotypes (Ras
2HOL
2, Ras
2HOL
+, Ras
+HOL
2, and
Ras
+HOL
+) (Figure S4). The MNU-induced tumors that were
observed in the mice of each group are shown in Table 1. A high
incidence of papilloma and carcinoma were observed in the
Ras
+HOL
2 and Ras
+HOL
+ mice but not in the Ras
2HOL
2 and
Ras
2HOL
+ mice. The tumor incidence in the Ras
+HOL
2 and
Ras
+HOL
+ mice was the same as that observed in the rasH2 mice
[23,24]. These mice were intraperitoneally administrated luciferin
every week. These results indicate that the HOL and Tyr
c
transgenes and the luciferin treatment do not influence MNU-
induced tumor incidence in rasH2 mice.
Bioluminescence imaging of HIF-1 activity in Tg mice
with both Ras and HOL transgenes after MNU treatment
Finally, we monitored HIF activity in MNU-treated Ra-
s
2HOL
+ and Ras
+HOL
+ Tg mice by in vivo bioluminescence
imaging. Since FVB/HOL mice repeatedly showed stronger
bioluminescence signals than the BALB/HOL ones (Figure S5),
we used mice from the FVB background in the assay. Six mice (8–
9 weeks old, 3 males and 3 females) were intraperitoneally injected
with MNU and then imaged every week until the 26
th week. All
the Ras
+HOL
+ mice (a–f) showed a significant bioluminescence
signal (Figure 4A), while none of the Ras
2HOL
+ mice had a
significant bioluminescence signal (Figure S6). Three Ras
+HOL
+
mice (a, e, and f in Figure 4A) and 2 Ras
2HOL
+ mice (g and h in
Figure S6) died during the observation period. Either at the time of
death or at the end of the experimental period, all the mice were
examined for tissue lesions, with the major tissues investigated by
histopathological analysis. The results are summarized in Table 2.
A strong bioluminescence signal was detected in papillomas of the
scrotum as early as the fifth week in all of the male Ras
+HOL
+
mice (yellow arrowheads in Figures 4A, 4B, and S7). Moreover, all
the Ras
+HOL
+ mice (a–f) had significant bioluminescence signals
in the abdominal region as early as the ninth week (Figure 4A). Ex
vivo imaging was also performed for the mice still alive at the end of
the experimental period in order to confirm that the tissues had a
bioluminescence signal (Figures 4C and 4D). The tissues with the
bioluminescence signal were histopathologically analyzed and
diagnosed as squamous cell papilloma/carcinoma (Figure 4C) or
adenocarcinoma in the forestomach and hemangioma in the liver
(Figure 4D). These results strongly suggest that HIF-1 activity is
closely associated with cancer formation.
Discussion
This is the first report of a mouse model for in vivo bioimaging of
endogenous cancer formation, and it was accomplished by using 2
Tg mouse lines, HOL and rasH2.
The HOL Tg mice sensitively provided information on HIF-1
transcriptional activity at the site of disease as well as in healthy
tissues (Figure 3). During the first week after birth, HIF-1 activity
was high, consistent with previous reports that HIFs and specific
HIF target genes are actively involved in maturational processes
during embryonic, fetal, and postnatal development by modulat-
ing cell differentiation, vascular development, angiogenesis, and
metabolic homeostasis [27,28]. No significant signal was detected
in the body .3 weeks after birth (Figures 3A and 3B), indicating
Figure 1. Generation and characterization of HOL transgenic mice. (A) Schematic representation of HRE/ODD-luciferase transgene. The
promoter contains 5 tandem repeats of the hypoxia responsive element (HRE) of human vascular endothelial growth factor gene. The reporter gene
encodes a fusion protein consisting of the nuclear localization signal (NLS) of the simian vacuolating virus 40 T-antigen, the oxygen-dependent
degradation domain (ODD) of human HIF-1a (548–603) and the firefly luciferase. (B) FVB/HOL and BALB/HOL mice were intraperitoneally injected
with 3,4,5-trihydroxybenzoic acid propyl ester (PG). The bioluminescence imaging was performed 4 h after PG injection. The experiment was
repeated three times, and the representative data are shown. (C) Southern blot analysis of the PstI-digested genome of the BALB/c, BALB/HOL, FVB/N,
and FVB/HOL mice. The blot was probed with the reporter cDNA fragment of the transgene.
doi:10.1371/journal.pone.0026640.g001
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tissues and that high levels of sustained HIF-1 activity would
indicate an abnormal status for tissues. Although there are
significant number of reports that HIF-1 activity plays key role
in tumor growth and malignancy, little information is available on
the role of HIF-1 transcriptional activity during endogenous tumor
development. By using double (Ras
+HOL
+) Tg mice, we
successfully monitored MNU-induced carcinogenesis (Figure 4).
The double (Ras
+HOL
+) Tg mice developed papillomas and
carcinomas at a frequency similar to what had been observed for
rasH2 mice treated with MNU (Table 1, Table 2 and Ref.
[23,24]). The results demonstrate that HIF-1 activity was detected
in most, if not all, cancers and papillomas as early as 9 weeks after
MNU treatment (Figure 4A), indicating that HIF-1 activity is
involved in papilloma formation and in the early stages of tumor
development. These results strongly suggest that the Ras
+HOL
+
Tg mice would be useful for studying the initial events of tumor
formation in vivo.
Mice c and h had alveolar/bronchiolar adenoma in the lung,
while no detectable bioluminescence signal was observed around
the chest. One explanation is that the small size of the cancers
resulted in a signal that was below the detection limits of the
Figure 2. In vitro analysis of the HOL reporter response to HIF-1 activation. (A) MEF cells from FVB/HOL (Tg) and FVB/N (non-Tg) mice were
cultured under hypoxic conditions (1% O2) for the indicated time, and luciferase activity was measured. The experiments were performed in triplicate,
and the mean luciferase activity 6 SD is shown in the graph. *P,0.05, **P,0.005. (B) FVB/HOL mice were peritoneally injected with PG, and 2 h later
RNA was isolated from the indicated tissues. RT-PCR analysis was performed with the isolated RNA. Glyceraldehyde-3-phosphate dehydrogenase was
used as an internal control. +, indicates a transgene used as a template; 2, indicates no template. The experiment was performed in triplicates, and
the representative data are shown. (C) FVB/HOL (Tg) and FVB/N (non-Tg) mice were peritoneally injected with PG, and 2 h later the mice were
injected with luciferin through the tail vain; 2 min later, the tissues were isolated and observed by ex vivo bioluminescent imaging. a, liver; b,
intestine; c, lung; d, uterus; e, kidney; f, spleen and pancreas; g, heart; h, thymus; i, bladder.
doi:10.1371/journal.pone.0026640.g002
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from deep organs are difficult to detect; the externally detected
signal from the lung (,5 mm depth) has been shown to be about
1/80 of that from the skin (,0.5 mm depth) [29]. Moreover, when
we performed immunohistochemical analysis, we failed to detect
luciferase protein expression in the tissues that showed significant
bioluminescent signal during the in vivo and ex vivo observations.
This is probably due to the short half-life (17 min) of the ODD-
luciferase reporter protein; the ODD polypeptide fused to the
luciferase accelerates the degradation of the luciferase, allowing
the detection of real-time HIF-1 activity in vivo [18].
Recently, a Tg ROSA26 ODD-Luc/+ mouse line for the in vivo
monitoring of HIF PHD activity was reported [30]. In these mice,
thereporterprotein ODD(530–652)-luciferase,underthe control of
a cytomegalovirus promoter, was constitutively expressed at a high
level in all tissues, with PHD function monitored through the
reduction in luciferase activity [30]. The effects of regulatory factors
other than PHDs on HIF-1 are also important in the monitoring of
HIF-1 activity in cancerous cells [5–17]. Therefore, it would be
difficult to precisely detect tumor formation by the Tg mice.
Our findings indicate that Ras
+HOL
+ mice hold significant
potential as a novel, alternative in vivo model to the lifetime mouse
bioassay for determining the carcinogenic potential of chemicals.
The Tg rasH2 mouse model has been one of the most thoroughly
tested in vivo alternatives to the lifetime mouse bioassay for both
nongenotoxic and genotoxic compounds [31,32]. As regulatory
and industry experience with the use of this model in
carcinogenicity testing has grown, there has been increasing
scientific and regulatory consensus that the model has added value
to drug safety testing and risk assessment for the carcinogenicity of
pharmaceuticals [31,32]. In particular, it has been used in the
internal decision-making process in terms of whether to advance a
compound or to investigate the potential mechanisms of
carcinogenicity [33]. Bioassays using Ras
+HOL
+ mice may be
able to further shorten the assessment period. If so, it would
contribute both to the earlier termination of clinical programs for
nonviable compounds and to the earlier redirection of a
development program for a viable candidate, leading to the
acceleration of new drug development. More importantly, from
the point of view of animal welfare, the early detection of cancer
would help avoid unnecessary pain and stress for the mice, and the
smaller number of required animals would contribute to the goals
of reducing and refining animal use. Although further studies using
other carcinogens are needed for comparing the sensitivity
between rasH2 and Ras
+HOL
+ mice, the results presented here
demonstrate that HIF-based in vivo bioluminescence imaging is a
reliable strategy for detecting carcinogenesis.
Collectively, the results suggest that the Tg mice presented here
w o u l db eu s e f u la sam o u s em o d e lf o rin vivo bioimaging to investigate
the onset and progression of cancers as well as other diseases related to
HIF-1 activity and for developing drugs and treatment strategies for
those diseases.
Figure 3. In vivo analysis of the HOL reporter response to HIF-1 activation. (A, B) The HIF-1 activity after birth. FVB/HOL mice were
peritoneally injected with luciferin on the indicated day after birth, and bioluminescent images were acquired 20 min later. (A) Representative images
are shown. (B) Total whole body photon counts were measured 4, 11, 18, 25, 39, 46, and 53 days after birth, and the photon counts (photon counts/s/
mm
3) in the region of interest are shown as values normalized to that of day 4 (n=5). Results are given as the means 6 SEM. (C) The femoral artery
was ligated and cut without damaging the nevus femoralis. A sham operation was performed on the ipsilateral side. Changes in bioluminescence
were monitored sequentially at indicated time periods after the operation. (D, E) Seven days after the ligation surgery of the femoral vessels, RNA was
isolated from the skeletal muscle of the mice legs, and semi-quantitative real-time RT-PCR was performed. GLUT1 (D) and HIF-1a (E), known as HIF-1
target genes, from the mRNA of the ischemic hindlimb muscle of the mice was quantified and normalized relative to the 18S rRNA level (n=3).
Results are given as the means 6 SD. *P,0.05.
doi:10.1371/journal.pone.0026640.g003
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Ethics statement
All animal experiments were performed with the approval of the
Animal Ethics Committees of the Central Institute for Experi-
mental Animals (CIEA; No. 08028), Kyoto University (No. Mde
Kyo 09247), and Tokyo Institute of Technology (No. 2010008)
and in accordance with the Ethical Guidelines for Animal
Experimentation of the CIEA, Kyoto University, and Tokyo
Institute of Technology.
Development of HOL transgenic (Tg) mouse
All mice used to generate the present Tg mice were purchased
from CLEA Japan Inc. (Tokyo, Japan). Construction of the
transgene, 5HRE-CMVmp-NLS-ODD(548–603)-(firefly luciferase),
which contains 5 tandem repeats of the hypoxia-response element,
a minimal cytomegalovirus promoter, and cDNAs encoding the
nuclear localization signal sequence of the Simian vacuolating virus
40 T-antigen, the human hypoxia-inducible factor 1a (HIF-1a)
oxygen-dependent degradation domain 548–603 (ODD548–603),
and firefly luciferase (Figure 1A), has been reported elsewhere [18].
The Tg mice were developed by microinjecting the 2.2 kb
transgene fragment into fertilized eggs with a C57BL/6J mice
background. Two lines of Tg mice were obtained. To facilitate
bioimaging, the coat color was exchanged by further backcross
mating of BALB/cA mice for more than 17 generations. The Tg
mouseline used inthefurther experimentswasnamedBALB/HOL
(formally, C.C6-Tg[HRE-HIF1AODD/luc]2Skk/JKyo). Further-
more, the same transgene was injected into the fertilized eggs with a
FVB/N mouse background. A Tg mouse line was established by
mating these syngeneic mice. This line (formally, FVB-Tg[HRE-
HIF1AODD/luc]2Skk/NKyo) is described in the text as FVB/
HOL.
Development of the rasH2-albino and rasH2-albino/HOL
Tg mouse
C57BL/6J-Tg(HRAS)2/Jic (rasH2), C57BL/6J-Tyr
c (B6-albi-
no), BALB/cAJcl, and MCH:ICR/Jcl mice were used to develop
the rasH2-albino and rasH2-albino/HOL Tg mice. The rasH2
mice were maintained at CIEA. The B6-albino mice were
purchased from Charles River Inc. (Kanagawa, Japan). BALB/
cAJcl and MCH:ICR/Jcl mice were purchased from CLEA Japan,
Inc. (Tokyo, Japan). All mice were reared in plastic cages
(19062456130 mm; CLEA Japan), with 3 animals per cage, in
an animal room with controlled temperature at 24uC62uC,
humidity at 60%615%, 12–25 air ventilations/h, and 12 h of
artificial lighting (08:00–20:00). Commercial diet was supplied ad
libitum. Filtered tap water was sterilized with ultraviolet (UV)
radiation and supplied ad libitum for drinking using a water bottle.
The mice were subjected to a 1 week acclimatization period before
treatment.
To generate rasH2 mice with white fur to facilitate bioimaging,
B6-albino mice were mated to the rasH2 mice. Offspring carrying
the rasH2 transgene were selected by genotyping with a
multiplexed PCR to amplify the 510- and 130-base pair (bp) Tg
products and the 260-bp non-Tg product as previously described
[23]. For genotyping, genomic DNA was extracted from the tails
of the resulting offspring using an automatic DNA extraction
apparatus (MagExtractor System MFX-9600, Toyobo, Osaka,
Japan) according to the manufacturer’s instructions. The rasH2-
albino mice were obtained by further intercross mating of selected
offspring carrying the rasH2 transgene and by checking their
genotypes and fur color.
The rasH2-albino/HOL Tg mice were generated by in vitro
fertilization between sperm from rasH2-albino male mice and
unfertilized eggs from BALB/HOL Tg mice. The fertilized eggs
were transplanted into the oviducts of pseudopregnant MCH:ICR
female mice to obtain offspring. Mice carrying the HOL and rasH2
transgenes were genotyped using the respective PCR primer sets to
amplify the transgenes. For genotyping of the ODD transgene, a
forward primer (59-AGACTTGGAGATGTTAGCTCCCTA-
Figure 4. In vivo bioimaging of cancer formation. (A) Double
(Ras
+HOL
+) transgenic mice were peritoneally injected with MNU and
bioluminescence images were acquired every week. Bioluminescent
signals from the papilloma of the scrotum are indicated by yellow
arrowheads. (B) Brightfield image (upper left), in vivo bioluminescence
image (upper right), and tumor section (bottom) of the squamous cell
papilloma of the scrotum from mouse c. (C) Brightfield image (upper
left), ex vivo bioluminescence image (upper right), and tumor section
(bottom) of the squamous cell papilloma/carcinoma of the stomach
from mouse b. (D) Ex vivo bioluminescence image (upper) and the
tumor section (bottom) of the hemangioma of the liver from mouse c.
bar=1 mm.
doi:10.1371/journal.pone.0026640.g004
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GAAGGACTCTGGCACA-39) were used, and the resulting
specific product size was 700 bp.
Carcinogenicity test by N-methyl-N-nitrosourea
administration
Fifteen mice each of the offspring, CB6F1-albino (Ras
2HOL
2),
CB6F1-albino-rasH2 (Ras
+HOL
2), CB6F1-albino-HOL(Ra-
s
2HOL
+), and CB6F1-albino-rasH2-HOL (Ras
+HOL
+), were
used for the carcinogenicity test by administration of N-methyl-
N-nitrosourea (MNU) as previously described [24]. At 6–7 weeks
of age, the mice were intraperitoneally injected once with 75 mg/
kg of MNU (Nacalai Tesque, Kyoto, Japan) in citrate buffer at
pH 4.5.
After administration, the mice were kept under daily observa-
tion to check for death. Mice were intraperitoneally injected with
10 mL/kg of D-luciferin (Promega, Madison, WI, USA) solution in
phosphate-buffered saline (PBS]) every week. Twenty-six weeks
after administration or at death or during an emergency, animals
were necropsied and systemic visual observations were performed.
Stomach (forestomach and glandular stomach), liver, kidneys,
spleen, heart, lungs, thymus, and lymph nodes and any sites
showing abnormalities were removed and fixed in 10% neutral
buffered formalin. The tissues were embedded in paraffin and
their 5-mm thick sections were prepared and stained with
hematoxylin and eosin.
In vivo and ex vivo bioluminescence imaging
In vivo and ex vivo bioluminescence imaging was conducted as
described previously [34]. Briefly, for the in vivo photon counts
assessing bioluminescence, mice were intraperitoneally injected
with 10 mL/kg of D-luciferin solution (10 mg/mL in PBS) and
placed in an IVIS Spectrum in vivo photon-counting device
(Caliper Life Sciences, Alameda, CA, USA). Bioluminescence
Table 2. Histopathological analysis of rasH2-HOL and FVB/HOL mice treated with N-methyl-N-nitrosourea.
Mouse Sex Tissues Histopathological diagnosis
RasH2- A = Stomach Squamous cell papilloma
HOL Scrotum Squamous cell papilloma
(Ras
+HOL
+)B = Stomach Squamous cell papilloma
Legs Squamous cell papilloma
Scrotum Squamous cell papilloma
C = Lung Alveolar/bronchiolar adenoma
Liver Hemangioma
Stomach Squamous cell papilloma/adenocarcinoma
Scrotum Squamous cell papilloma
D R Stomach Squamous cell papilloma/carcinoma
E R Hematopoietic system Malignant lymphoma
Stomach Squamous cell papilloma
F R Hematopoietic system Malignant lymphoma
Stomach Squamous cell papilloma
FVB/HOL G = Hematopoietic system Malignant lymphoma
(Ras
2HOL
+)H R Lung Alveolar/bronchiolar adenoma
I = No significant lesion
J = No significant lesion
K R No significant lesion
L R No significant lesion
doi:10.1371/journal.pone.0026640.t002
Table 1. Tumor incidence rate in transgenic mice after N-methyl-N-nitrosourea treatment.
Genotype
Squamous cell carcinoma/papilloma
(Stomach) Squamous cell papilloma (Skin) Malignant lymphoma (Hematopoietic system)
Ras
2HOL
2 6.7%* 0% 60%
Ras
+HOL
2 87.5% 37.5% 50%
Ras
2HOL
+ 0% 0% 55.6%
Ras
+HOL
+ 62.5% 37.5% 75%
*Tumor incidence rate. Carcinogenicity test of 15 mice from each of the following offspring type: CB6F1-albino (Ras
2HOL
2), CB6F1-albino-rasH2 (Ras
+HOL
2), C6F1-
albino-HOL (Ras
2HOL
+), and CB6F1-albino-rasH2-HOL (Ras
+HOL
+) were performed by administering N-methyl-N-nitrosourea. The mice that were alive at the end of the
experimental period were necropsied, and systemic visual observations were performed.
doi:10.1371/journal.pone.0026640.t001
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D-luciferin. For ex vivo imaging, mice were sacrificed immediately
after the in vivo imaging, and bioluminescence images of the body
and organs were acquired within 10 min of the in vivo imaging.
The following conditions were used for image acquisition:
exposure time, 2 min (for in vivo) or 1 min (for ex vivo); lamp level,
high; binning, medium: 8; field of view, 19619 cm (for in vivo) and
12.9612.9 cm (for ex vivo); f/stop, 1. The bioluminescence was
analyzed using Living Image 3.10 software (Caliper Life Sciences).
Because of the background bioluminescence of the untreated mice
(from the D-luciferin injection) was ,3,500 photon counts/s, we
considered signals of .3,500 photon counts/s to be significant.
The minimum and maximum bioluminescent signals (photons/s/
cm
2/sr) are 3,500 and 10,000, respectively, if not otherwise
indicated in a figure with a rainbow bar scale.
PG treatment
PG (3,4,5-trihydroxybenzoic acid propyl ester; Sigma-Aldrich
Co., St. Louis, MO, USA) dissolved in ethanol (100 mg/mL) was
diluted 1:10 in PBS immediately before intraperitoneal adminis-
tration (100 mg/kg).
RT-PCR for reporter gene expression
The mice were dissected 2 h after PG administration. Tissues
were removed, and total RNA samples were extracted from the
tissues with TRIzol reagent (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s protocol. Tissue cDNA was
produced by reverse transcription, and the HOL reporter cDNA
fragment was amplified by PCR using primer pairs 59-
ODD(+):AGA CTT GGA GAT GTT AGC TCC CTA TAT
CC-39 and 59-Luc(2):TCT TGT CCC TAT CGA AGG ACT
CTG GCA CA-39.
Southern blot analysis
Genomic DNA was prepared from the mouse tail by the
conventional phenol/chloroform method. DNA samples were
digested with PstI applied to agarose gel electrophoresis and
transferred to a nitrocellulose membrane. The transgene integrat-
ed into the mouse genome was detected with a DNA probe labeled
with [
32P]-dCTP by Ready Prime Labelling Kit (GE Healthcare,
Waukesha, WI, USA) according to the manufacturer’s protocol
using the 2.2-kb transgene fragment.
Luciferase reporter assay
Luciferase reporter assay used basically the same method as
previously described [35]. Briefly, 10
5 cells were first seeded onto
12-well plate in 2 mL of 5% fetal bovine serum/Dulbecco’s
Modified Eagle Medium and cultured overnight, then further
cultured under hypoxic (1% O2) conditions for the indicated time.
The cells were then washed with PBS and lysed with 100 mL passive
lysis buffer (Promega) under hypoxic conditions. Luciferase activity
was measured using a luminometer (Lumat LB 9507; Berthold
Technologies, Bad Wildbad, Germany) after the addition of 50 mL
of a substrate reagent (luciferin; Promega) to the 25 mL of cell lysate.
Ischemic treatment
Mice were anesthetized by intraperitoneal pentobarbital
injection (50 mg/kg), and the femoral vessels in right inguinal
area were exposed. The femoral artery was ligated proximally and
distally using 6-0 silk sutures and cut between the ligatures without
damaging the nevus femoralis. The overlying skin was closed using
4-0 silk sutures. A sham operation was performed on the ipsilateral
side.
Measurement of GLUT1 expression
Seven days after the ligation surgery of the femoral vessels, the
mice(n=3)werekilled,andthe RNAfromtheskeletalmuscle ofthe
mice legs was treated with DNase and purified using an RNeasy kit
(QIAGEN, Venlo, The Netherlands). First-strand synthesis and
real-time PCR reaction were performed using QuantiTect SYBR
Green PCR Kit (Qiagen) following the protocol provided by the
company. The PCR reaction and detection were performed using a
7300 real-time PCR system (Applied Biosystems, Foster City, CA,
USA). The PCR primers were purchased from QIAGEN. Using
semi-quantitative real-time RT-PCR, GLUT1, known as the HIF-1
target gene, mRNA of the mice ischemic hindlimb muscle was
quantified. The RT-PCR data were quantified and normalized
relativetothe18S rRNAlevel.Thefold inductionwascalculated on
the average value of the ipsilateral non-ischemic legs. Results shown
represent mean 6 standard deviations.
Statistical analysis
Statistical analyses used the Student t test. Values of P,0.05
were considered statistically significant. Pearson correlation
coefficient was used to evaluate the correlation of the data sets.
Supporting Information
Figure S1 Background bioluminescence of FVB/N mice.
Wild-type FVB/N mice were either injected peritoneally with PG
or were not injected with PG (none). Two hours later luciferin was
injected and bioluminescence images were acquired 20 min after
luciferin injection. The image acquisition conditions were the same
as those described for Figure 1b.
(TIF)
Figure S2 Fluorescence in situ hybridization analysis of
the FBV/HOL genome. G-band (left) and R-band (right)
analyses of the chromosomes. The arrowhead shows the signal on
the R-band. The map of chromosome 19 is shown below.
Experimental method was shown in Text S1.
(TIF)
Figure S3 Bioluminescence in newborns. One-day-old
FVB/HOL (Tg) and FVB/N (Non-Tg) mice were injected with
D-luciferin (0.5 mg/50 mL/body). After 10 min, the biolumines-
cence images were acquired.
(TIF)
Figure S4 Generation of mice used in the 6-mo protocol
for carcinogenicity assessment. A total of 300 offspring were
produced by in vitro fertilization of sperm from B6-Tyr
c-rasH2 male
mice into unfertilized eggs from BALB/HOL female mice, followed
by transplantation into the oviducts of pseudo-pregnant MCH:ICR
female mice. Results of the genotyping of 125 females are shown in
Table 1. The production rates of mice with Ras
+HOL
+ and
Ras
2HOL
+ were 19.2% and 17.8%, respectively, that were slightly
lower than the ratio expected according to Mendelian law.
(TIF)
Figure S5 Comparison of the strength of the biolumi-
nescent signal between BALB/HOL and FVB/HOL mice
(representative images). Upper panels show photos of the
papillomas from the rasH2-BALB/HOL and the rasH2-FVB/
HOL mice. Lower panels show bioluminescence images of the
papillomas. The papillomas in the rasH2-BALB/HOL mice were
much larger than the ones in the rasH2-FVB/HOL mice, whereas
the bioluminescent signal in the papillomas of the rasH2-FVB/
HOL mice was always stronger.
(TIF)
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mo protocol for carcinogenicity assessment. (G–L) The
FVB/HOL mice did not show significant bioluminescent signals
during the period of the experiment. The image acquisition
conditions were the same as those for Figure 4A. Mice G and H
died 22 weeks after the N-methyl-N-nitrosourea (MNU) treat-
ment.
(TIF)
Figure S7 Images of papillomas. Photos of the papillomas in
mice A and B were taken 18 weeks after the N-methyl-N-
nitrosourea treatment.
(TIF)
Figure S8 The alveolar/bronchiolar adenoma from
mouse C. Bright field image of the lung (left) and tumor section
(right, 650) of the alveolar/bronchiolar adenoma (yellow arrow
head in the left panel) from mouse C. Bar=3 mm.
(TIF)
Text S1 FISH analysis.
(DOCX)
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